GlassScriptPhysician profile
Brooke L Blumetti
NPI 1245488444
$6,177.42
in general payments reported to CMS, 2019-2025
25 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,104 · 2020: $388 · 2021: $349 · 2022: $914 · 2023: $867 · 2024: $1,513 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,149 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,148.85 |
| Education | $273.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,096.42 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Lilly USA, LLC | $601.87 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $557.72 | 2019-2024 | Otezla |
| Janssen Biotech, INC. | $541.56 | 2020-2025 | Tremfya |
| Incyte Corporation | $354.64 | 2022-2025 | Opzelura |
| Pfizer INC. | $327.98 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $320.58 | 2019-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $276.92 | 2019-2025 | |
| Galderma Laboratories, L.P. | $274.76 | 2019-2024 | Aklief |
| Dermavant Sciences, INC. | $262.90 | 2024 | Vtama |
| Genzyme Corporation | $251.36 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $219.26 | 2020-2024 | Dupixent, Libtayo |
| Ucb, INC. | $211.71 | 2024-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $201.11 | 2019-2025 | Jublia |
| Arcutis Biotherapeutics, INC. | $149.20 | 2023-2025 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $138.91 | 2025 | Sofdra |
| Celgene Corporation | $120.48 | 2019 | |
| Organon LLC | $106.21 | 2025 | Vtama |
| Almirall LLC | $39.98 | 2023-2025 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $39.46 | 2022-2023 | Sotyktu |
| Vyne Pharmaceuticals INC. | $22.04 | 2020 | |
| Leo Pharma INC. | $21.65 | 2020 | |
| Boston Scientific Corporation | $17.34 | 2023 | Upsylon |
| Merck Sharp & Dohme LLC | $15.68 | 2019 | |
| Mayne Pharma Commercial LLC | $7.68 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Blumetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.